An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 10, 2016-12 ,pp. : 1240-1252

Bentham Science Publishers

Access to resources Recommend Favorite

Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease

By Singh Sarika   Das T.   Ravindran A.   Chaturvedi R.K.   Shukla Y.   Agarwal A.K.   Dikshit M.  

Redox Report, Vol. 10, Iss. 2, 2005-04 ,pp. : 103-109

Maney Publishing

Access to resources Recommend Favorite

Motor and Non-Motor Features of Parkinson's Disease – A Review of Clinical and Experimental Studies

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 4, 2012-06 ,pp. : 439-449

Bentham Science Publishers

Access to resources Recommend Favorite

The Chemokine CXCL10 as a Therapeutic Target in Animal Models of Neuroinflammatory Disease

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 10, 2006-12 ,pp. : 683-688

Bentham Science Publishers

Access to resources Recommend Favorite

Models and mechanisms of anxiety: evidence from startle studies

By Grillon Christian  

Psychopharmacology, Vol. 199, Iss. 3, 2008-08 ,pp. : 421-437

Springer Publishing Company

Access to resources Recommend Favorite